Hardtech startup moves into Houston area with new Conroe facility, eyes tests in space

LEADING TECH

FluxWorks, a hardtech startup, opened its new home-base in Conroe, Texas. Photo courtesy FluxWorks

FluxWorks, a hardtech startup, recently opened its new base of operations in Workhub Developments’ Conroe location.

Founded in College Station by CEO Bryton Praslicka, FluxWorks specializes in making contactless magnetic gears for use in extreme conditions. At 9,000 square feet, the new Conroe facility is a result of discussions with Governor Greg Abbott's office and the Greater Houston Partnership, who introduced the company’s leadership to the Conroe Economic Development Council, encouraging their move, Praslicka tells InnovationMap.

“The pieces of the puzzle were all there, and with the support of the local, state, and federal government, we were thrilled to move to Conroe,” Paslicka says.

CEO Bryton Praslicka founded the company in College Station. Photo courtesy FluxWorks

The enterprise recently won the MassChallenge’s technology in space prize, allowing them to test four gears at the International Space Station (ISS) National Laboratory in 2026. The prize is funded by Boeing and the Center for the Advancement of Science in Space, or CASIS which runs the ISS. Praslicka says their new offices will expand their manufacturing capacity by having all levels of production on-site.

"Since our inception, FluxWorks has been fragmented, having an office in one location, manufacturing in another location, and testing in a third location," Praslicka explains. "This is a new chapter for us to begin having the entire process, from design to testing and validation and then shipping to customers, all under one house.”

The magnetic gears FluxWorks makes are suited to space applications because they do not require lubricants, which can be difficult to control at harsh temperatures and in microgravity, to minimize friction. Through their partnership with the ISS, Praslicka says FluxWorks has strengthened their connections to other space tech companies including Axiom and Boeing, and it's opened the door to collaborations with the new Texas Space Commission.

“Now the NASA Johnson Space Center is even officially supporting our proposal to the Texas Space Commission as a proposed teaming partner,” Praslicka says.

The new facility received special security certification from the National Institute of Standards and Technology, increasing FluxWorks’ opportunities to work with NASA and defense contractors. The Texas Manufacturing Assistance Center awarded FluxWorks for “outstanding innovation” during its recent ribbon cutting ceremony.

The company, named a finalist for the 2024 Houston Innovation Awards, cleaned up in the 2023 Rice Business Plan Competition with a $350,000 investment prize from Houston group, Goose Capital.

FluxWorks has moved into its 9,000-square-foot facility in Conroe. Photo courtesy FluxWorks

From Your Site Articles
At a research facility just outside of Houston, scientists have found a plant that has COVID-19 treatment potential. Photo courtesy of iBio

Houston-area company is harvesting plant technology for treatment of chronic diseases and COVID-19

growing a cure

The original version of this story included some factual inaccuracies due to misinformation from a source. The story below has been corrected.

In a 130,000 square-foot facility outside of Bryan-College Station, iBio is growing the makings of new types of therapeutics for fibrosis, cancer, and even COVID-19.

The company, which moved its headquarters from New York to Texas in July, uses novel biopharma methods to produce the vital molecules and antigens used for vaccines and other types of medical treatments through plants in a fast, sustainable way.

Other methods of creating biopharmaceutical require scientists to engineer cells to create a desired protein, which can be one of the most time consuming parts of the process, IBio's CEO Tom Isett explains. However, through iBio's FastPharming method, the team let's the plants do most of the work.

IBio introduces an Agrobacterium carrying a desired gene to manipulate the plant's DNA.

"[The bacteria] takes over the machinery of the plant leaves and it then produces the protein of interest or the biopharmaceutical that we were going to want to make for people," Isett says.

IBio then harvests the leaves and purifies the proteins to make the biopharmaceutical of interest. The entire process can save anywhere from six to 18 months in development, he estimates.

Too, if there's demand for more of the product, through this process, all scientists need to do is grow more plants.

"We have a linear scale up, it's very straightforward," says Peter Kipp, iBio's VP of translational science and alliance management. "And using some of the other competing methodologies, as you go to a bigger scale, you have new technical problems that you have to solve, but we don't."

The team discovered that an Australian species of the tobacco plant could be one of their biggest conduits in their process.

"It just grows like a weed. And that's why we like it," Kipp says.

The plant expends most of its energy in creating its leaves, where IBio extracts most of its proteins from. The plants are grown in the company's indoor, vertical hydroponic facility and are able to be harvested about every six weeks, and (it's important to note) does not contain nicotine.

IBio used their FastPharming process to introduce two vaccine candidates and a therapeutic in about six week's time. However, Isett says they're not just a COVID-19 vaccine company.

"We're mostly focused in other areas. But when [COVID] showed up, we did want to go in and see if we could address it using the speed of our system," he says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas falls to bottom of national list for AI-related job openings

jobs report

For all the hoopla over AI in the American workforce, Texas’ share of AI-related job openings falls short of every state except Pennsylvania and Florida.

A study by Unit4, a provider of cloud-based enterprise resource planning (ERP) software for businesses, puts Texas at No. 49 among the states with the highest share of AI-focused jobs. Just 9.39 percent of Texas job postings examined by Unit4 mentioned AI.

Behind Texas are No. 49 Pennsylvania (9.24 percent of jobs related to AI) and No. 50 Florida (9.04 percent). One spot ahead of Texas, at No. 47, is California (9.56 percent).

Unit4 notes that Texas’ and Florida’s low rankings show “AI hiring concentration isn’t necessarily tied to population size or GDP.”

“For years, California, Texas, and New York dominated tech hiring, but that’s changing fast. High living costs, remote work culture, and the democratization of AI tools mean smaller states can now compete,” Unit4 spokesperson Mark Baars said in a release.

The No. 1 state is Wyoming, where 20.38 percent of job openings were related to AI. The Cowboy State was followed by Vermont at No. 2 (20.34 percent) and Rhode Island at No. 3 (19.74 percent).

“A company in Wyoming can hire an AI engineer from anywhere, and startups in Vermont can build powerful AI systems without being based in Silicon Valley,” Baars added.

The study analyzed LinkedIn job postings across all 50 states to determine which ones were leading in AI employment. Unit4 came up with percentages by dividing the total number of job postings in a state by the total number of AI-related job postings.

Experts suggest that while states like Texas, California and Florida “have a vast number of total job postings, the sheer volume of non-AI jobs dilutes their AI concentration ratio,” according to Unit4. “Moreover, many major tech firms headquartered in California are outsourcing AI roles to smaller, more affordable markets, creating a redistribution of AI employment opportunities.”

Houston energy trailblazer Fervo closes $462 million Series E

Fresh Funds

Houston-based geothermal energy company Fervo Energy has closed an oversubscribed $462 million series E funding round, led by new investor B Capital.

“Fervo is setting the pace for the next era of clean, affordable, and reliable power in the U.S.,” Jeff Johnson, general partner at B Capital, said in a news release.

“With surging demand from AI and electrification, the grid urgently needs scalable, always-on solutions, and we believe enhanced geothermal energy is uniquely positioned to deliver. We’re proud to support a team with the technical leadership, commercial traction, and leading execution capabilities to bring the world’s largest next-generation geothermal project online and make 24/7 carbon-free power a reality.”

The financing reflects “strong market confidence in Fervo’s opportunity to make geothermal energy a cornerstone of the 24/7 carbon-free power future,” according to the company. The round also included participation from Google, a longtime Fervo Partner, and other new and returning investors like Devon Energy, Mitsui & Co., Ltd., Mitsubishi Heavy Industries and Centaurus Capital. Centaurus Capital also recently committed $75 million in preferred equity to support the construction of Cape Station Phase I, Fervo noted in the release.

The latest funding will support the continued buildout of Fervo’s Utah-based Cape Station development, which is slated to start delivering 100 MW of clean power to the grid beginning in 2026. Cape Station is expected to be the world's largest next-generation geothermal development, according to Fervo. The development of several other projects will also be included in the new round of funding.

“This funding sharpens our path from breakthrough technology to large-scale deployment at Cape Station and beyond,” Tim Latimer, CEO and co-founder of Fervo, added in the news release. “We’re building the clean, firm power fleet the next decade requires, and we’re doing it now.”

Fervo recently won Scaleup of the Year at the 2025 Houston Innovation Awards, and previously raised $205.6 million in capital to help finance the Cape Station earlier this year. The company fully contracted the project's capacity with the addition of a major power purchase agreement from Shell this spring. Fervo’s valuation has been estimated at $1.4 billion and includes investments and support from Bill Gates.

“This new investment makes one thing clear: the time for geothermal is now,” Latimer added in a LinkedIn post. “The world desperately needs new power sources, and with geothermal, that power is clean and reliable. We are ready to meet the moment, and thrilled to have so many great partners on board.”

---

This article originally appeared on EnergyCapitalHTX.com.

Baylor center receives $10M NIH grant to continue rare disease research

NIH funding

Baylor College of Medicine’s Center for Precision Medicine Models received a $10 million, five-year grant from the National Institutes of Health last month that will allow it to continue its work studying rare genetic diseases.

The Center for Precision Medicine Models creates customized cell, fly and mouse models that mimic specific genetic variations found in patients, helping scientists to better understand how genetic changes cause disease and explore potential treatments.

The center was originally funded by an NIH grant, and its models have contributed to the discovery of several new rare disease genes and new symptoms caused by known disease genes. It hosts an online portal that allows physicians, families and advocacy groups to nominate genetic variants or rare diseases that need further investigation or new treatments.

Since its founding in 2020, it has received 156 disease/variant nominations, accepted 63 for modeling and produced more than 200 precision models, according to Baylor.

The center plans to use the latest round of funding to bring together more experts in rare disease research, animal modeling and bioinformatics, and to expand its focus and model more complex diseases.

Dr. Jason Heaney, associate professor in the Department of Molecular and Human Genetics at BCM, serves as the lead principal investigator of the center.

“The Department of Molecular and Human Genetics is uniquely equipped to bring together the diverse expertise needed to connect clinical human genetics, animal research and advanced bioinformatics tools,” Heaney added in the release. “This integration allows us to drive personalized medicine forward using precision animal models and to turn those discoveries into better care for patients.”

View All Listings